TIGECYCLINE PRODUCTS MARKET ANALYSIS

Market Challenges And Opportunities

Global Tigecycline Products Market: Drivers

The increasing prevalence of gonorrhea in the U.S. is driving demand for tigecycline products in the market. For instance, according to the Centers for Disease Control and Prevention’s 2017 report, in the U.S, around 555,608 cases of gonorrhea were reported. Therefore, pharmaceutical companies are focusing on launching products for treatment of bacterial infections due to increasing prevalence. For instance, in 2017, Sandoz Inc. launched AP-rated generic version of Tygacil (Tigecycline) injection at a cheaper price compared to branded products in order to increase affordability of the drug. These factors are expected to drive growth of global tigecycline products market.

Global Tigecycline Products Market: Restraints

Tigecycline antibiotic is characterized by side effects such as lower back or side pain, painful or difficult urination, problems with vision or hearing, cough or hoarseness, fever or chills, and headache. Moreover,the use of  tigecycline is restricted due to increase in mortality in hospital-acquired or ventilator-associated pneumonia. Moreover, patients prefer oral tablets (amoxicillin) to injection (tigecycline) for treatment of bacterial infection, due to the cost effectiveness of oral amoxicillin. Cost of 500 mg amoxicillin oral tablet is US$ 23.99, while cost of the tigecycline injection is US$ 79.22. These factors are expected to restrain growth of the global tigecycline products market.

Global Tigecycline Products Market: Market Drivers

The increasing prevalence of gonorrhea in the U.S. is driving demand for tigecycline products in the market. For instance, according to the Centers for Disease Control and Prevention’s 2017 report, in the U.S, around 555,608 cases of gonorrhea were reported. Therefore, pharmaceutical companies are focusing on launching products for treatment of bacterial infections due to increasing prevalence. For instance, in 2017, Sandoz Inc. launched AP-rated generic version of Tygacil (Tigecycline) injection at a cheaper price compared to branded products in order to increase affordability of the drug. These factors are expected to drive growth of global tigecycline products market.